Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kairos Pharma (KAPA) Cash from Operations (2024 - 2025)

Kairos Pharma (KAPA) has disclosed Cash from Operations for 2 consecutive years, with 805000.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Operations fell 379.17% year-over-year to 805000.0, compared with a TTM value of 5342000.0 through Jun 2025, changed N/A, and an annual FY2024 reading of 3955000.0, down 4982.72% over the prior year.
  • Cash from Operations was 805000.0 for Q2 2025 at Kairos Pharma, down from 714000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 36000.0 in Q1 2024 and bottomed at 2020000.0 in Q3 2024.